Wall Street Zen Upgrades Vaxart (NASDAQ:VXRT) to "Hold"

Vaxart (NASDAQ:VXRT - Get Free Report) was upgraded by investment analysts at Wall Street Zen to a "hold" rating in a research note issued on Thursday.

Separately, B. Riley cut their target price on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a research note on Thursday, March 27th.

Vaxart Trading Up 4.3%

Shares of Vaxart stock traded up $0.02 during trading hours on Thursday, reaching $0.48. The stock had a trading volume of 267,808 shares, compared to its average volume of 2,422,885. The stock's 50 day moving average is $0.41 and its 200 day moving average is $0.57. The firm has a market capitalization of $108.86 million, a PE ratio of -1.16 and a beta of 1.27. Vaxart has a twelve month low of $0.29 and a twelve month high of $1.07.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07). The business had revenue of $20.88 million during the quarter, compared to the consensus estimate of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. As a group, sell-side analysts predict that Vaxart will post -0.39 earnings per share for the current year.

Insider Transactions at Vaxart

In related news, insider Steven Lo bought 100,000 shares of the business's stock in a transaction dated Monday, May 19th. The stock was acquired at an average price of $0.49 per share, with a total value of $49,000.00. Following the completion of the purchase, the insider now directly owns 100,000 shares of the company's stock, valued at approximately $49,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 2.90% of the company's stock.

Institutional Trading of Vaxart

Several large investors have recently bought and sold shares of VXRT. Raymond James Financial Inc. purchased a new stake in Vaxart during the 4th quarter valued at about $129,000. Sequoia Financial Advisors LLC grew its stake in Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 35,213 shares in the last quarter. Geode Capital Management LLC grew its stake in Vaxart by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock valued at $1,723,000 after acquiring an additional 57,911 shares in the last quarter. Invesco Ltd. grew its stake in Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after acquiring an additional 24,803 shares in the last quarter. Finally, Silverarc Capital Management LLC grew its stake in Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock valued at $714,000 after acquiring an additional 77,782 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.